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Edited by Judit Ova´diAbstract To assess the etiology of inﬂuenza-associated enceph-
alopathy (IAE), a surveillance eﬀort was conducted during 2000–
2003 in South-West Japan. All fatal and handicapped patients
except one (4/34 patients) exhibited a disorder of mitochondrial
b-oxidation evoked by the inactivated carnitine palmitoyltrans-
ferase II (CPT II) with transiently elevated serum acylcarnitine
ratios (C16:0 + C18:1)/C2 > 0.09 during high-grade fever. Analy-
ses of genotypes and allele compositions of CPT II revealed a
thermolabile phenotype of compound heterozygotes for
[1055T > G/F352C] and [1102G > A/V368I], which shows a
higher frequency in IAE patients than healthy volunteers
(P < 0.025). The thermolabile phenotype of CPT II variations
may be a principal genetic background of IAE in Japanese.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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inactivation1. Introduction
Inﬂuenza-associated encephalopathy (IAE) is a severe neu-
rologic complication of inﬂuenza infection which is known to
be distinct from Reyes syndrome [1,2]. The number of cases
of IAE has increased in recent years, with more than 100 chil-
dren aged below 5–6 years dying annually from IAE in Japan
[3,4]. IAE results in high morbidity and mortality and is char-
acterized by a high-grade fever accompanied within 12–48 h by
febrile convulsions, often leading to coma and multiple-organ
failure. Because the frequency of IAE is higher in Japanese
than it is in Caucasians, it is possible that genetic factors play
an important role in the aetiology of IAE.
During the last four inﬂuenza seasons of 2000–2003, we con-
ducted a survey to investigate the etiology and constitutional
predispositions in patients susceptible IAE in South-West
Japan. We found that almost all fatal or handicapped IAE pa-
tients exhibited transiently elevated the serum levels of long-
chain acylcarnitines during high-grade fever >40 C. The result
suggests that the high-risk patients have thermolabile genetic*Corresponding author. Fax: +81 88 633 7425.
E-mail address: kido@ier.tokushima-u.ac.jp (H. Kido).
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lism. In the present study, we report thermolabile carnitine pal-
mitoyltransferase II (CPT II) variation, predominantly found
in Japanese IAE children, and discuss the etiology of IAE as
a thermolabile phenotype of polymorphic variation.2. Materials and methods
2.1. Patients
This investigation was approved by the ethics review committee for
human genome analysis at our institution. All participants granted
their written informed consent. Surveillance for IAE was conducted
during the inﬂuenza seasons of 2000 through 2003 in South-West Ja-
pan, and a total of 34 patients were diagnosed as having IAE. The
diagnosis of IAE was made according to the clinical signs of the disease
[3]. All 34 patients had viral antigen, the abrupt onset of seizure and
coma that occur within 12–48 h after beginning of a high-grade fever,
although these patients did not have previous episodes. One patient
(patient #21) had ingested dichophenac sodium at the onset of fever
and later died, but fatty degeneration in the liver, a typical pathological
ﬁnding of Reyes syndrome [5,6], was not observed. Thirteen IAE pa-
tients, four familial relations of patient #21 and 79 healthy volunteers
agreed to undergo the genome analyses.
2.2. Clinical data analyses
EDTA-treated peripheral blood, urine and specimens from throat
swabs were obtained from the patients. Proﬁles of organic acids in
urine and acylcarnitines in serum were analyzed by gas chromatogra-
phy–mass spectrometry [7] (Shimazu Qp5000 Model, Shimazu, Kyoto,
Japan) and electrospray tandem mass spectrometry [8] (TSQ7000
Model, Thermo-Quest, Tokyo, Japan), respectively. Inﬂuenza virus
antigen was detected by enzyme-linked immunosorbent assay
(Becton–Dickinson) in specimens from throat swabs.
2.3. Assay of CPT II activity
CPT II activities were measured in the homogenates of liver biopsies
and COS-7 cells transfected with wild-type (WT) and polymorphic var-
iant CPT II cDNAs in the presence of 1% Tween 20 in the reaction
mixture, by detecting of the palmitoyl-L-[methyl-3H]carnitine formed
from L-[methyl-3H] carnitine and palmitoyl-CoA [9]. For the analysis
of the heat stability of WT and variants of CPT II, the activities of liver
and cellular homogenates were measured after incubating the samples
at 37 and 41 C.
2.4. Analysis of genomic CPT II
Genomic DNA from whole blood was puriﬁed as previously de-
scribed [10]. PCR of ﬁve exons of the CPT II gene was carried
out with intron-based primers (Table 1) in genomic DNA. For hap-
lotype analysis the CPT II exon 4 region was cloned into pCR2.1blished by Elsevier B.V. All rights reserved.
Table 1
Exon primers used for PCR ampliﬁcation of the CPT2 gene; MA or MB primer used for variant induction
Region Forward primer Reverse primer Product size (bp)
Exon 1 cttgtgtttagactccagaactcc gtcatgagtgactgcagtcaggttg 292
Exon 2 ctgtcagccttacactgaccc aactctcggggcttggtc 305
Exon 3 tttagggctatgctgttggg aggaagggaggatgagacgt 358
Exon 4-1 ctctggaggttgatgccatt acccaagcactgaggacaag 1472
Exon 4-2 tagagttcagtgggtagctggct atccaggcacatctgaagtac 401
Exon 5 tttcctgaggtccttttccatcctg atgaggaagtgatggtagcttttca 425
MA-V352I ggcacaaaccgctggtgtgataaat atttatcacaccagcggtttgtgc
MB-V368I ctactgccgtccactttagcactcttg caagagtgctcaaagtggacggcagtag
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CPT II gene were analyzed with the ABI DyeDeoxy Terminator
Cycle Sequencing Kit on an ABI-PRISM 3100 Genetic Analyzer
(PE-Applied Biosystems). Each PCR product was sequenced in both
strands, and the analysis was performed at least twice indepen-
dently.
2.5. Expression of WT and variant CPT IIs in COS-7 cells
A full-length WT CPT II cDNA clone (pCMV6-WT) containing the
entire coding region of human CPT II was a gift of V. Esser, the Uni-
versity of Texas. Plasmid pCNV6-WT was used as a parental vector to
generate three full-length variant CPT II cDNA clones, pCMV6-MA
[1055T > G/F352C], pCMV6-MB [1102G > A/V368I] and pCMV6-
MA + B [1055T > G/F352C] + [1102G > A/V368I] by means of a
QuickChange site-directed mutagenesis Kit (Stratagene). The primers
used for variant induction are listed in Table 1. The substitutions and
integrity of the CPT II cDNAs were conﬁrmed by sequence analysis.
pSVb-Galactosidase control vector (Promega) was co-transfected with
various pCMV-6-CPT II plasmids as an internal standard for the mon-
itoring of transfection eﬃciency. Mock transfection was also carried
out as control. After transfection for 72 h, COS-7 cells were washed
twice with saline and CPT II activities of WT and variants were
analyzed.Fig. 1. Distribution of (C16:0 + C18:1)/C2 ratios of the patients with
IAE at the time of high-grade fever/convulsion and normal temper-
ature conditions. The acylcarnitine ratios of patients suﬀering from
IAE, and the family members of patient #21 and one volunteer
without infection were analyzed. Upper cut-oﬀ range = 0.048 and high-
risk patient range = 0.09 are indicated by the thin dashed and bold
dashed lines, respectively. (+) Fatal; (m) handicapped; (*) brother, who
had the same genotype as in patient #21.3. Results
3.1. Patients and acylcarnitine ratios
Thirty-four patients (22 male and 12 female) with no under-
lying disease, ranging in age from 0 to 16 years, with a mean
age of 4.7 ± 2.8 years, had IAE. Inﬂuenza A, B and A + B
virus antigen were detected in nasopharyngeal swabs at
91.2%, 5.9% and 2.9%, respectively. A single patient (patient
#21, which was one of the fatal cases) used dichrophenac dur-
ing the inﬂuenza episode.
Laboratory tests of patient serum revealed that 41.2% of the
IAE patients exhibited characteristic elevations of serum
acylcarnitine ratios [11] (C16:0 + C18:1)/C2 > 0.048 an upper
cutoﬀ value [8,11] (Fig. 1). In particular, over half the patients
in the severe IAE group (seven patients), i.e., those with the ra-
tios >0.09, turned to fatal (three female) and handicapped (one
male) outcomes. These data indicate that patients in the high-
risk group have a marked disorder(s) of mitochondrial long-
chain fatty acid metabolism. The most common inborn errors
of mitochondrial fatty acid b-oxidation and related metabo-
lism in Japanese are due to CPT II deﬁciency, with an accumu-
lation of long-chain acylcarnitine in serum and glutaric
aciduria type 2 (GA2) at 26.6% and 21.9%, respectively [12];
however, the frequency of these are relatively low at 11%
and 5.5%, respectively, in Caucasians, who have the most com-
mon deﬁciency of medium-chain acyl-CoA dehydrogenase
(MCAD), which occurs at about 36.6% [13]. The
(C16:0 + C18:1)/C2 ratios of all IAE patients tested, however,
normalized or decreased to the borderline ratios between0.048 and 0.06 at normal temperature after febrile convulsion.
These results suggest that the ratios are transiently elevated
during febrile convulsions at >40 C. Familial relations except
the mother of patient #21, who carried thermolabile pheno-
type of CPT II, as described below, exhibited borderline ratios
between 0.042 and 0.054 under normal temperature, and a
brother who had identical alleles with patient #21, exhibited
the ratio of 0.051. Two patients in the high-risk group with ra-
tios >0.09 recovered after infection for 3–4 weeks without any
sequelae.
There was one fatal IAE patient (patient #16) with the ratio
of 0.004 (Fig. 1), who was diagnosed GA2 based upon an
abnormal urinary organic acid proﬁle (data not shown), a dis-
order of electron transfer in mitochondria. All the other IAE
patients with the ratios <0.09 recovered without any severe
sequelae. Octanoylcarnitine, a diagnostic marker of MCAD
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patients so far.
3.2. Thermolability of CPT II variants
To further study the temperature dependence of the acylcar-
nitine levels shown in Fig. 1, liver biopsies were obtained from
patient #21 and from one control patient. The speciﬁc activity
of CPT II of patient #21, who had the highest acylcarnitine ra-
tio of 0.168, was 0.4 ± 0.06 nmol/min/mg protein, being about
36% normal control (1.1 ± 0.3 nmol/min/mg protein, n = 6) at
37 C. It is noteworthy that this patients CPT II was extremely
thermolabile and the speciﬁc activity was reduced to about
50% after incubation for 120 min at 41 C, although control
CPT II was reduced only slightly, to 91.4%, under the same as-
say conditions (Fig. 2). In order to analyze the etiology of theTable 2
Genotypes and allele compositions of CPT II between IAE patients and hea
Genotypes Patients
n Frequency (%)
Type 1 (F352F-V368V-M647M) 0 0
Type 2 (F352F-I368I-V647V) 0 0
Type 3 (F352F-V368I-M647V) 1 7.7
Type 4 (F352F-I368I-M647V) 1 7.7
Type 5 (F352F-I368I-M647M) 3 23.1
Type 6 (F352F-V368I-M647M) 2 15.4
Type 7 (C352C-I368I-M647M) 1 7.7
Type 8 (F352C-I368I-M647M) 1 7.7
Type 9 (F352C-V368I-M647M) 4 30.8
Total 13
*Haplotypes not determined.
Fig. 2. Time courses of change in the activities of CTP II from the liver
homogenates of control and patient #21 at 37 and 41 C. Data are
presented as means ± S.D. (n = 6).thermolability of the patients CPT II, we analyzed the geno-
types of patient #21 and her familial relations. Sequence anal-
yses of the CPT II gene revealed that the patient possessed
compound heterozygous variations, i.e., [1055T > G/
F352C] + [1102G > A/V368I], and no other reported CPT II
mutations and polymorphisms [15] were detected. The
F352C substitution has been reported only in Japanese and
not in Caucasians to date, and the V368I polymorphic varia-
tion is found in both races but has relatively mildly deleterious
eﬀects related to CPT II deﬁciency [15,16]. Her brother also
had heterozygous and the father had homozygous compound
variations for [1055T > G/F352C] + [1102G > A/V368I]. The
sister had heterozygous variation for [1055T > G/
F352C] + homozygous variation for [1102G > A/V368I] and
the mother had only heterozygous variation for [1102G > A/
V368I]. Although a polymorphism [1939A > G/M647V] of
CPT II reported [15] was not found in patient #21 and her
familial relations, it was found in several IAE patients tested,
but no signiﬁcant diﬀerence was observed in the frequency be-
tween IAE patients and healthy volunteers (Table 2).
Haplotype analysis of the pedigree of patient #21 and the
levels of acylcarnitine ratios of her familial relations revealed
that haplotype CIM was commonly observed among patient
#21 and her relations (father, brother and sister), who exhib-
ited the borderline acylcarnitine ratios at normal temperature
(Fig. 3). During febrile convulsions at >40 C, acylcarnitine le-
vel of patient #21, who had the same alleles as in the brother,
may increase to the high-risk ratios >0.09. The mother of pa-
tient #21 without haplotype CIM exhibited normal acylcarni-
tine ratio.
Genotypes and allele compositions of CPT II between IAE
patients and healthy volunteers are shown in Table 2. Among
nine genotypes observed, the frequency of type 9 (FVM-CIM
alleles), being identical to the genotype of patient #21, was sig-
niﬁcantly higher than that in healthy volunteers (P < 0.025).
There was no other variation with a signiﬁcantly higher fre-
quency than that found in healthy volunteers has been identi-
ﬁed in IEA patients to date, perhaps because of the limited
number of patients analyzed.
3.3. Expression of F352C and V368I CPT II polymorphic
variants and their thermal instability
For in vitro expression of WT and the variant CPT II
cDNAs, four cDNAs were overexpressed in COS-7 cells
(Fig. 4): pCMV6-WT containing WT CPT II (FVM-CPT II);lthy volunteers
Healthy volunteers Alleles P
n Frequency (%)
11 13.9 FVM-FVM
1 1.2 FIV-FIV
3 3.8 FVM*-FIV*
1 1.2 FIM-FIV
25 31.6 FIM-FIM
27 34.2 FVM-FIM
5 6.3 CIM-CIM
0 0 FIM-CIM
6 7.6 FVM-CIM <0.025
79
Fig. 3. Haplotype analysis of the pedigree of patient #21 and levels of
acylcarnitine ratios of the familial relations. Haplotypes of CPT II
gene (FVM, FIM and CIM) are illustrated. Serum aclycarnitine ratios
at normal temperature (father, mother, sister and brother) and
acylcarnitine ratio of patient #21 during febrile convulsions at
>40 C (*). (black) Acylcarnitine ratios >0.09; (gray) borderline
acylcarnitine ratios; (white) normal acylcarnitine ratios.
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II); pCMV6-MB containing the [1102G > A/V368I] (FIM-
CPT II); and pCMV6-MA + B containing the [1055T > G/
F352C] + [1102G > A/V368I] (CIM-CPT II). The CPT II
activity of vector alone was 0.27 ± 0.03 nmol/min/mg protein
(n = 5), being consistent with endogenous enzyme activity,
and all of the following data presented have the value of
CPT II activity of the vector alone subtracted. The CPT II
activity of the COS-7 cells overexpressed with pCMV6-WT
was 0.46 ± 0.07 nmol/min/mg protein. The CPT II activities
of the CVM-CPT II, FIM-CPT II and CIM-CPT II exhibited
as 62.8 ± 7.2%, 102.5 ± 19.6% and 34.7 ± 1.3% of the WT
FVM-CPT II activity, respectively, at 37 C. Next we analyzed
WT and the variant CPT II activities under heat stress condi-
tions at 41 C. Although the activity of WT FVM-CPT II was
slightly decreased to 91% at 41 C during incubation forFig. 4. Comparison of the activities of WT and CTP II variants
overexpressed in COS-7 cells at 37 and 41 C. CPT II activities of WT
(FVM-CPT II), the [1055T > G/F352C] (CVM-CPT II), the
[1102G > A/V368I] (FIM-CPT II) and the [1055T > G/
F352C] + [1102G > A/V368I] (CIM-CPT II) were measured at 37
and 41 C. Data are presented as means ± S.D. (n = 5).120 min, those of FIM-, CVM- and CIM-CPT II were de-
creased to 91%, 48% and 72%, respectively, at 41 C, in com-
parison with those at 37 C. Among these variants, the
enzyme activity of both CIM- and CVM-CPT II was signiﬁ-
cantly reduced to about 25–30% of WT FVM-CPT II activity
at 37 C. These data support the inactivation in CPT II activity
seen in patient #21 at 41 C in Fig. 2, although these results are
from the homozygous changes of [1055T > G] and
[1102G > A] alleles of CPT II.4. Discussion
Encephalitis/encephalopathy is a commonly encountered
pediatric disorder in various clinical forms. Among these,
IAE has been reported as a complication of inﬂuenza, and is
of particularly high frequency in Japanese children [3]. In the
present study, we found that 41.2% of IAE patients exhibit
an elevated serum acylcarnitine ratio – (C16:0 + C18:1)/
C2 > the upper cutoﬀ value of 0.048 – during febrile convulsion
and 57% of the high-risk patients with ratios of >0.09 took a
clinical turn towards death or severe sequelae. This ratio is a
marker of long-chain fatty acid metabolism disorder and the
most common disorder of this sort in Japan is due to a CPT
II deﬁciency [12]. In the studied group there was one fatal
GA2, disorder of electron transfer in mitochondria, the patient
having the value <0.048. These results indicate that all the se-
vere IAE patients who took a clinical turn to fatality (four pa-
tients) and severe sequelae (one patient) had disorders of
mitochondrial energy metabolism. It is particularly note-
worthy that elevated acylcarnitine ratios at the time of high-
grade fever were then signiﬁcantly decreased under a return
to normal temperature in all of the follow-up patients. These
ﬁndings suggest that a continuous high-grade fever, often ac-
companied by fasting, evokes a systemic and metabolic energy
crisis, particularly in the patient with thermolabile poly-
morphic variations or a deﬁciency of energy metabolizing
enzymes.
The children having the most common inborn errors of
mitochondrial fatty acid b-oxidation, such as CPT II deﬁciency
and GA2 in Japanese with the approximate frequencies of 1/
100000 [12,17], suﬀer severe acute encephalopathy and multi-
ple-organ failure (Reyes-like syndrome) without infection.
Our present data indicate that severe IAE patients who exhibit
thermolabile CPT II are the carriers of haplotype CIM. The
allelic frequency of F352C in the Japanese population reported
is 0.21 but the variation has not been reported among Cauca-
sian populations [16]. The allelic frequencies of V368I and
M647V are 0.70 and 0.04, respectively, in the Japanese popu-
lation [16] and 0.51 and 0.25, respectively, in Southern Euro-
pean populations [18].
In the present study, we found thermolabile phenotype of
CPT II variations in IAE patients, and propose these varia-
tions as susceptibility variants of IAE. CPT II, however, is
not a rate-limiting enzyme of the metabolic pathway of b-oxi-
dation and when CPT II activities are above 30% those of con-
trol, fatty acid oxidation is usually found within the normal
range [15]. Under heat stress conditions at 41 C, the CPT II
activities of patient #21 and the transfected CIM- and
CVM-CPT II were below 30% of WT CPT II at 37 C. In re-
gard to the three polymorphic variations of CPT II, such as
2044 Y. Chen et al. / FEBS Letters 579 (2005) 2040–2044F352C, V368I and M647V, 9 genotypes out of 27 expected
genotypes were observed in the IAE patients and healthy vol-
unteers, as shown in Table 2. Among these, diﬀerence in the
frequencies of type 9 (F352C-V368I-M647M) in IAE patients
was signiﬁcantly high between the two groups. Although type
7 (C352C-I368I-M647M) showed the lowest enzyme activity in
Fig. 4, diﬀerences in the frequencies of type 7 between IAE pa-
tients and healthy volunteers were not signiﬁcant, probably be-
cause of the limited number of IAE patients analyzed. The
CIM haplotype, as measured in COS-7 cells, was moderately
temperature sensitive, while the CPT II in the liver from pa-
tient #21 showed more drastic temperature sensitivity. These
results suggest that, in addition to the heat-stress by tempera-
ture, the metabolic stress by increased fatty acid oxidation ﬂux
during fever and fasting may contribute signiﬁcantly, and/or
an involvement of variations of another energy metabolizing
enzymes which synergistically induce energy crisis in combina-
tion with CPT II variations. Although the molecular mecha-
nisms of the encephalopathy and acute brain edema seen in
IAE patients with a disorder of mitochondrial b-oxidation
have yet to be clariﬁed, the accumulation of mini-plasmin in
the cerebral capillaries in mice with a congenital or acquired
abnormality of mitochondrial b-oxidation, and the resulting
proteolytical destruction of the blood–brain barrier after inﬂu-
enza virus infection [19], might prove to be one of the related
etiologic factors.
Considering the energy metabolism disorder of IAE patients
with thermolabile phenotype of CPT II polymorphic varia-
tions, hypothermia therapy, administration of L-carnitine for
activation of long-chain fatty acid b-oxidation, and an admin-
istration of glucose to increase the rate of the citric acid cycle,
might prove to be highly therapeutic when confronted with
cases of IAE.
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